Danil G M Molin

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7011469/daniel-g-m-molin-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers1,088
citations16
h-index32
g-index51
ext. papers1,362
ext. citations4.9
avg, IF4.11
L-index

#	Paper	IF	Citations
47	Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy Journal of Clinical Oncology, 2022, JCO2102407	2.2	1
46	Polyphosphate-Based Hydrogels as Drug-Loaded Wound Dressing: An In Vitro Study. <i>ACS Applied Polymer Materials</i> , 2022 , 4, 2871-2879	4.3	Ο
45	Checkpoint CD47 expression in classical Hodgkin lymphoma British Journal of Haematology, 2022,	4.5	1
44	Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). <i>Blood</i> , 2021 , 138, 1366-1366	2.2	3
43	Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021 , 106, 2502-2506	6.6	2
42	Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 1671-1681	7.8	4
41	Thiol-ene Reaction: An Efficient Tool to Design Lipophilic Polyphosphoesters for Drug Delivery Systems. <i>Molecules</i> , 2021 , 26,	4.8	3
40	Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. <i>Acta Oncolgica</i> , 2021 , 60, 771-778	3.2	0
39	Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000᠒014, focusing on patients aged⊡-60 years. <i>EJHaem</i> , 2021 , 2, 400-412	0.9	O
38	Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma. <i>Cardio-Oncology</i> , 2021 , 7, 6	2.8	2
37	Pembrolizumab in relapsed or refractory Richter syndrome. <i>British Journal of Haematology</i> , 2020 , 190, e117-e120	4.5	14
36	CD30 expression and survival in posttransplant lymphoproliferative disorders. <i>Acta Oncolgica</i> , 2020 , 59, 673-680	3.2	3
35	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020 , 189, 661-671	4.5	8
34	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 950-954	1.9	6
33	Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma. <i>Immunobiology</i> , 2020 , 225, 151872	3.4	1
32	(Sub)populations of extracellular vesicles released by TNF-\(\text{H}\)triggered human endothelial cells promote vascular inflammation and monocyte migration. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1801	1 ¹⁶ 53 ⁴	14
31	No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. <i>British Journal of Haematology</i> , 2020 , 188, 685-691	4.5	10

(2016-2019)

30	Electrical stimulation promotes the angiogenic potential of adipose-derived stem cells. <i>Scientific Reports</i> , 2019 , 9, 12076	4.9	11
29	Phosphodiester Hydrogels for Cell Scaffolding and Drug Release Applications. <i>Macromolecular Bioscience</i> , 2019 , 19, e1900090	5.5	5
28	Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival. <i>Upsala Journal of Medical Sciences</i> , 2019 , 124, 105-110	2.8	1
27	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 376-384	1.9	16
26	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019 , 134, 1144-1153	2.2	148
25	High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. <i>British Journal of Haematology</i> , 2019 , 184, 192-	204 ⁵	12
24	An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. <i>European Journal of Haematology</i> , 2018 , 100, 88-97	3.8	16
23	Maintaining bovine satellite cells stemness through p38 pathway. Scientific Reports, 2018, 8, 10808	4.9	34
22	Extracellular Vesicles Work as a Functional Inflammatory Mediator Between Vascular Endothelial Cells and Immune Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 1789	8.4	55
21	Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?. <i>Annals of Hematology</i> , 2018 , 97, 2129-2135	3	8
20	Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome. <i>Acta Oncolgica</i> , 2018 , 57, 276-282	3.2	11
19	Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. <i>PLoS ONE</i> , 2018 , 13, e0204870	3.7	17
18	Synthesis of Functional Polymer Particles from Morita-Baylis-Hillman Polymerization. <i>Macromolecular Rapid Communications</i> , 2018 , 39, e1800678	4.8	3
17	Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. <i>British Journal of Haematology</i> , 2017 , 177, 449-456	4.5	14
16	Direct detection of nano-scale extracellular vesicles derived from inflammation-triggered endothelial cells using surface plasmon resonance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 1663-1671	6	26
15	High proportions of PD-1 and PD-L1 leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. <i>Blood Advances</i> , 2017 , 1, 1427-1439	7.8	26
14	In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy. <i>International Journal of Pharmaceutics</i> , 2016 , 503, 150-62	6.5	17
13	CXCL1 microspheres: a novel tool to stimulate arteriogenesis. <i>Drug Delivery</i> , 2016 , 23, 2919-2926	7	4

12	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016 , 173, 236-44	4.5	24
11	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016 , 127, 1531-8	2.2	105
10	The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. <i>European Journal of Haematology</i> , 2016 , 97, 430-438	3.8	19
9	Low molecular weight poly (2-dimethylamino ethylmethacrylate) polymers with controlled positioned fluorescent labeling: Synthesis, characterization and in vitro interaction with human endothelial cells. <i>International Journal of Pharmaceutics</i> , 2015 , 478, 278-287	6.5	5
8	Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes. <i>Transplantation</i> , 2015 , 99, 1036-42	1.8	9
7	A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. <i>Acta Oncol</i> g ica, 2014 , 53, 669-79	3.2	62
6	Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma. <i>Histopathology</i> , 2012 , 61, 26-32	7-3	8
5	Online measurement of collagen synthesis in smooth muscle cells. Toward non-destructive analysis of matrix production in vascular tissue engineered grafts. <i>FASEB Journal</i> , 2011 , 25, 1127.4	0.9	
4	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). <i>Nature Genetics</i> , 2010 , 42, 1126-1130	36.3	158
3	Therapeutic angiogenesis in the heart: protect and serve. Current Opinion in Pharmacology, 2007, 7, 158	3- 63	45
2	Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. <i>Upsala Journal of Medical Sciences</i> , 2004 , 109, 179-228	2.8	18
1	Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002 , 119, 122-4	4.5	139